b+pharma Belgium: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
b+pharma Belgium
Largest movements
- Receivables within one year +€289,494
up €289,494 (+13.8%), from €2.1m to €2.4m
of which Trade receivables: +€362,531
- Profit (loss) carried forward +€213,458
up €213,458 (+52.0%), from -€410,531 to -€197,073
- Tax, wage and social debts +€61,654
up €61,654 (+41.9%), from €147,132 to €208,786
- Depreciation -€16,733
down €16,733 (-90.3%), from €18,539 to €1,805
- Financial income -€8,646
down €8,646 (-52.2%), from €16,570 to €7,924
- Gross operating margin +€3,760
up €3,760 (+1.3%), from €283,264 to €287,023
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,131,639 | €2,391,558 | +€259,918 | +12.2% |
| Fixed assets | 21/28 | €19,745 | €0 | -€19,745 | -100% |
| Tangible fixed assets | 22/27 | €19,745 | €0 | -€19,745 | -100% |
| Furniture and vehicles | 24 | €19,745 | €0 | -€19,745 | -100% |
| Current assets | 29/58 | €2,111,894 | €2,391,558 | +€279,664 | +13.2% |
| Amounts receivable within one year | 40/41 | €2,093,830 | €2,383,324 | +€289,494 | +13.8% |
| Trade receivables | 40 | €1,100,239 | €1,462,770 | +€362,531 | +33.0% |
| Other amounts receivable | 41 | €993,591 | €920,554 | -€73,037 | -7.4% |
| Deferred charges and accrued income | 490/1 | €18,064 | €8,234 | -€9,830 | -54.4% |
| Total equity and liabilities | 10/49 | €2,131,639 | €2,391,558 | +€259,918 | +12.2% |
| Equity | 10/15 | €1,941,305 | €2,154,764 | +€213,458 | +11.0% |
| Contributions | 10/11 | €2,350,000 | €2,350,000 | = | 0.0% |
| Capital | 10 | €2,350,000 | €2,350,000 | = | 0.0% |
| Issued capital | 100 | €2,350,000 | €2,350,000 | = | 0.0% |
| Reserves | 13 | €1,836 | €1,836 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,836 | €1,836 | = | 0.0% |
| Legal reserve | 130 | €1,836 | €1,836 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€410,531 | -€197,073 | +€213,458 | +52.0% |
| Amounts payable | 17/49 | €190,334 | €236,794 | +€46,460 | +24.4% |
| Amounts payable within one year | 42/48 | €190,334 | €236,794 | +€46,460 | +24.4% |
| Trade debts | 44 | €43,202 | €28,008 | -€15,194 | -35.2% |
| Suppliers | 440/4 | €43,202 | €28,008 | -€15,194 | -35.2% |
| Taxes, remuneration and social security | 45 | €147,132 | €208,786 | +€61,654 | +41.9% |
| Taxes | 450/3 | €147,132 | €208,786 | +€61,654 | +41.9% |
| Non-recurring operating income | 76A | €0 | €15,024 | +€15,024 | |
| Remuneration, social security and pensions | 62 | €0 | - | = | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €18,539 | €1,805 | -€16,733 | -90.3% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €0 | -€111 | -€111 | |
| Other operating charges | 640/8 | €1,193 | €2,150 | +€957 | +80.2% |
| Gross operating margin | 9900 | €283,264 | €287,023 | +€3,760 | +1.3% |
| Operating profit (loss) | 9901 | €263,532 | €283,180 | +€19,647 | +7.5% |
| Financial income | 75/76B | €16,570 | €7,924 | -€8,646 | -52.2% |
| Recurring financial income | 75 | €16,570 | €7,924 | -€8,646 | -52.2% |
| Financial charges | 65/66B | €562 | €451 | -€111 | -19.8% |
| Recurring financial charges | 65 | €562 | €451 | -€111 | -19.8% |
| Profit (loss) for the period before taxes | 9903 | €279,541 | €290,653 | +€11,112 | +4.0% |
| Income taxes | 67/77 | €76,346 | €77,195 | +€849 | +1.1% |
| Profit (loss) for the period | 9904 | €203,195 | €213,458 | +€10,264 | +5.1% |
| Profit (loss) for the period to be appropriated | 9905 | €203,195 | €213,458 | +€10,264 | +5.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 18 October 2026 via checked.be.